Develop Next-Generation HIV Therapies

A high priority of NIH-sponsored research is to develop next-generation HIV therapies. Despite the advent of simplified daily combination treatments which provide sustained viral suppression, there is still a need to identify new long-acting medications with fewer side effects in parallel with the development of  novel  delivery and testing technologies to improve efficacy of and adherence to treatment. To achieve this goal, ERC-CFAR investigators are applying basic sciences  research and drug discovery strategies to identify new druggable targets that prevent viral assembly or virus-host interactions, develop new preclinical drug animal models and develop broadly neutralizing antibodies as a new sustained anti-HIV treatment. Listed below are NIH-funded studies by our ERC-CFAR Investigators researching strategies to develop Next-Generation HIV therapies.

Investigators Insitution NIH Grant Title
Felipe Diaz-Griffero  Einstein R01 AI087390  Modulation of Retroviral Uncoating by Cellular Factors
Paul Bieniasz  Rockefeller University R01 AI050111  RNA Protein Interactions in HIV-1 Replication
Paul Bieniasz  Rockefeller University R37 AI064003  Discovery and Mechanism of Antiretroviral Factors
Marina Caskey  Rockefeller University U01 AI129825  3BNC117 And 10-1074 to Suppress HIV-1 Replication and Reduce the Reservoir
Theodora Hatziioannou  Rockefeller University R01 AI078788  Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS